Clinical Trials · NCT01779466

Daytime Impact Sleep Study

TerminatedPhase 2Desmopressin (Prohibited)
Phase
Phase 2
Recruitment status
Terminated
Sponsor
Ferring Pharmaceuticals
Enrollment
5
Start date
Apr 2013
Locations
1 site, United Kingdom
Primary endpoint
Mean number of nocturnal voids
View Desmopressin compound reference